๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Head and Neck Cancer
Clinical trial register · China

Head and Neck Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 9 Shanghai 8 Beijing 4 Chengdu 4 Huizhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou9 Shanghai8 Beijing4 Chengdu4 Huizhou3
All 31 locations
Target enrolment
to

Head and Neck Cancer trials in China

33 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
NCT07766889Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
32
Guangzhou
2026-09-01
Recruiting
Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies
NCT07662681Head and Neck Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 1/2
40
Shanghai
2026-07-01
Recruiting
Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07662746Head and Neck Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
29
Shanghai
2026-07-01
Recruiting
Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
NCT07632339Head and Neck Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
102
Shanghai
2026-06-16
Recruiting
SGRT in Head and Neck Cancer Radiotherapy
NCT07726407Head and Neck Cancer, Radiotherapy, Conformal (IMRT)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
40
Guangzhou
2026-06-15
Not yet open
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
NCT07583316Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
Corregene Biotechnology Co., Ltd
Phase 1
192
Beijing
2026-05-29
Recruiting
A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions
NCT07532538Hypopharyngeal Cancer, Laryngeal Cancer, Head and Neck Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
3,000
Nanjing
2026-04-30
By invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Recruiting
Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy
NCT07467083Head and Neck Cancer
West China Hospital
Phase 3
170
Chengdu
2026-03-15
Recruiting
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
NCT07447570Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2025-10-15
Not yet open
A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things
NCT07126457Head and Neck Cancer, Radiation-Induced Mucositis
Nanfang Hospital, Southern Medical University
Not applicable
110
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09-01
Recruiting
Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis
NCT06307327Head and Neck Cancer, Radiation-Induced Mucositis
Nanfang Hospital, Southern Medical University
Observational
264
Guangzhou, Huizhou, Jieyang, Meizhou
2025-09
Active, closed
Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
NCT07435415Head and Neck Cancer, Local Recurrent Tumor
China Medical University Hospital
Phase EARLY_PHASE1
10
2025-08-01
Recruiting
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
NCT06952868Head and Neck Cancer, Boron Neutron Capture Therapy
China Medical University Hospital
Phase 2
24
2025-05-23
Recruiting
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
NCT07027280Head and Neck Cancer
First Affiliated Hospital of Chongqing Medical University
Observational
700
Chongqing
2025-02-27
Recruiting
Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
NCT06876844Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
24
Shanghai
2024-12-30
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Recruiting
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma
NCT06781567Adenoid Cystic Carcinoma, Head and Neck Cancer
HitGen Inc.
Phase 2
140
Shanghai
2024-12-13
Recruiting
U87 CAR-T in Patients With Advanced Head and Neck Tumors
NCT06614686Nasopharynx Cancer, Head and Neck Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
20
Shanghai
2024-09-20
Recruiting
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
NCT06494943Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Fudan University
Phase 1/2
27
Shanghai
2024-06-26
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Recruiting
Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
NCT06345287Head and Neck Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
133
Beijing
2024-01-01
Recruiting
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
NCT05777824Head and Neck Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
84
Beijin
2023-01-01
Recruiting
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
NCT05595590Head and Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Chengdu, Tianjin
2022-10-20
Active, closed
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871Breast Cancer, Head and Neck Cancer
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
NCT06879691Head and Neck Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 4
171
Baotou
2021-05-15
Active, closed
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
NCT01266044Head And Neck Cancer
M.D. Anderson Cancer Center
Phase 3
435
Shanghai
2011-12-09
Active, closed
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00956007Head and Neck Cancer
Radiation Therapy Oncology Group
Phase 3
702
Shatin
2010-03-31
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/head-and-neck-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies listing the condition Head and Neck Cancer.

How many Head and Neck Cancer trials are recruiting in China?

23 of the 33 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 6 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Head and Neck Cancer), 33 studies
PhaseStudiesRecruitingShare
Phase 2161248.5%
Observational5515.2%
Phase 1/2339.1%
Phase 3319.1%
Not applicable216.1%
Phase 1216.1%
Phase 4103%
Phase EARLY_PHASE1103%

Most active sponsors

Lead sponsors with the most studies (Head and Neck Cancer)
Lead sponsorStudiesRecruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University44
Nanfang Hospital, Southern Medical University32
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
China Medical University Hospital21
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University22
Sun Yat-sen University20
Tianjin Medical University Cancer Institute and Hospital22
Betta Pharmaceuticals Co., Ltd.11
Biotech Pharmaceutical Co., Ltd.10
Corregene Biotechnology Co., Ltd10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.